# MetaVia Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/MetaVia Inc.). ## Overview MetaVia Inc. is a clinical-stage biotechnology company developing novel pharmaceuticals for cardiometabolic diseases. Its current pipeline is focused on two programs targeting metabolic dysfunction-associated steatohepatitis (MASH) and obesity, with R&D spending centered on advancing those product candidates through clinical development. ## Products & services • Clinical-stage drug development for cardiometabolic diseases • Vanoglipel (DA-1241) MASH program • DA-1726 obesity program • Preclinical and clinical trial manufacturing support • Regulatory and third-party development services - **Lead clinical programs** (0%) — Core pipeline assets under development for MASH and obesity, including Vanoglipel (DA-1241) and DA-1726. - **Research and development services** (100%) — Internal and outsourced R&D activities such as CRO work, consultants, and clinical operations. - **Manufacturing and supply chain support** (0%) — Drug product manufacturing, storage, and CMO-related services used for preclinical and clinical studies. - **Licensing and collaboration arrangements** (0%) — Third-party licensing and shared-services arrangements that support development programs. - Clinical-stage drug development for cardiometabolic diseases - Vanoglipel (DA-1241) MASH program - DA-1726 obesity program - Preclinical and clinical trial manufacturing support - Regulatory and third-party development services ## Customers MetaVia does not sell commercial medicines yet; its primary stakeholders are clinical investigators, CROs, CMOs, and licensing partners that enable drug development. The eventual end customers would be physicians and patients in cardiometabolic disease markets, but near-term value creation depends on advancing the pipeline and securing financing or collaboration support. - **Clinical development vendors** (primary) — CROs, consultants, and trial operators that execute studies and provide development expertise. - **Manufacturing partners** (primary) — CMOs and related suppliers that make and store drug product for preclinical and clinical use. - **Licensing and collaboration partners** (secondary) — Third parties such as Dong-A ST that provide shared services, rights, or funding support. - **Future prescribers and patients** (emerging) — Physicians and patients in MASH and obesity markets who would use approved therapies if development succeeds. - CROs and consultants supporting clinical trial execution - CMOs producing drug product for studies - Licensing and collaboration partners funding development - Future physicians treating MASH and obesity patients - Future patients with cardiometabolic disease ## Geography MetaVia is a U.S.-based company and reports under U.S. GAAP, with operations centered on development activities rather than a broad commercial footprint. The excerpts provided do not disclose country-level revenue, which is consistent with a clinical-stage business that has not yet built a commercial sales base. - Headquartered in the United States - No country-level revenue disclosure in the excerpts - R&D and clinical work likely coordinated through U.S. operations - Third-party development and manufacturing may be global - Geographic exposure is mainly regulatory and trial-site related ## Strategy MetaVia's near-term strategy is to conserve capital while advancing its MASH and obesity programs through clinical development. Management also expects to supplement cash through equity, debt, or collaboration structures, which makes financing execution as important as scientific progress. - **Advance the MASH and obesity pipeline** (short-term) — Clinical progress is the main driver of future value and partnering optionality. - **Secure additional financing** (short-term) — The company expects current cash to fund operations only into 2026 and may need more capital to continue trials. - **Manage development spend and runway** (medium-term) — R&D is the primary cash use, so disciplined spending determines how long the pipeline can progress. - Advance Vanoglipel (DA-1241) and DA-1726 through development - Prioritize R&D spending on the highest-value pipeline assets - Use partnerships and out-licensing to extend funding runway - Raise capital through equity, debt, or warrant exercise - Preserve liquidity to avoid slowing or stopping clinical trials ## Risks MetaVia faces the typical risks of a clinical-stage biotech company: clinical failure, regulatory setbacks, and dependence on external capital. Its going-concern language, limited cash runway, and reliance on equity financing make dilution and trial delays material business risks. - **Going-concern and liquidity risk** [high] — The company states it expects cash to fund operations only into 2026 and may need additional capital. - **Clinical development failure** [critical] — Pipeline value depends on successful outcomes for Vanoglipel and DA-1726. - **Dilution from equity financing** [high] — Operations have been funded primarily through equity offerings and convertible securities. - **Regulatory and trial execution risk** [medium] — Clinical-stage companies depend on approvals, site execution, and compliance with regulatory requirements. - Clinical trial failure could eliminate value in the lead programs - Regulatory delays can extend timelines and increase burn - Funding risk may force trial slowdowns or stoppages - Equity raises and warrant exercise can dilute shareholders - Warrant fair value changes can add earnings volatility ## Accounting The most important accounting judgments are fair value estimates for stock-based compensation and warrant liabilities, both of which can move reported earnings without changing cash flow. R&D expense recognition is also important because costs are expensed as incurred across clinical, manufacturing, regulatory, and licensing activities, making quarterly results sensitive to trial timing and vendor spend. - **Warrant liability fair value** — Other income/expense - **Stock-based compensation** — Operating expenses and net loss - **Accrued expenses** — Operating liabilities and expense timing - **R&D expense recognition** — Reported operating loss - Fair value of warrant liabilities affects other income/expense - Stock-based compensation adds non-cash expense and volatility - Accrued expenses require judgment and can shift period costs - R&D costs are expensed as incurred, not capitalized - Clinical and manufacturing timing can create quarterly swings --- *Last updated: 2026-04-28T20:27:04.189959+00:00*